Figure 2From: A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors Dose–response relationship of huKS-IL2. Day 2, cycle 1, as shown by C max (a) and AUC 0–24h (b). Cmax, maximum or peak serum concentration; AUC0–24h, area under the concentration versus time curve from time zero to 24 hours after the start of infusion.Back to article page